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ABSTRACT
Matrix extracellular phosphoglycoprotein/osteo-
blast factor 45 (MEPE/OF45) was cloned in 2000
with functions related to bone metabolism. We
identified MEPE/OF45 for the first time as a new
co-factor of CHK1 in mammalian cells to protect
cells from DNA damage induced killing. We demon-
strate here that MEPE/OF45 directly interacts
with CHK1. Knocking down MEPE/OF45 decreases
CHK1 levels and sensitizes the cells to DNA damage
inducers such as ionizing radiation (IR) or campto-
thicin (CPT)-induced killing. Over-expressing wild-
type MEPE/OF45, but not the mutant MEPE/OF45
(depleted the key domain to interact with CHK1)
increases CHK1 levels in the cells and increases
the resistance of the cells to IR or CPT. MEPE/
OF45, interacting with CHK1, increases CHK1 half-
life and decreases CHK1 degradation through the
ubiquitine-mediated pathway. In addition, the inter-
action of MEPE/OF45 with CHK1 decreases CHK1
levels in the ubiquitin E3 ligases (Cul1 and Cul4A)
complex, which suggests that MEPE/OF45
competes with the ubiquitin E3 ligases binding to
CHK1 and thus decreases CHK1 from ubiquitin-
mediated proteolysis. These findings reveal an
important role of MEPE/OF45 in protecting cells
from DNA damage induced killing through
stabilizing CHK1, which would provide MEPE/OF45
as a new target for sensitizing tumor cells to radio-
therapy or chemotherapy.
INTRODUCTION
CHK1 is one of the essential checkpoint proteins
involved in cellular response to multiple DNA damage
inducers (1–4). It is believed that up-regulated CHK1
protects cells from ionizing radiation (IR) or
camptothecin (CPT)-induced killing (4–8), which is
related to the role of CHK1 in promoting homologous
recombination repair (9,10). Despite the importance of
CHK1 in DNA damage response, the regulation of
CHK1 in mammalian cells is not well understood, partly
because of its essential nature (3,11).
Matrix extracellular phosphoglycoprotein/osteoblast
factor 45 (MEPE/OF45) was originally cloned from a
human oncogenetic hypophosphatemia tumor (12) in
2000, and then was identiﬁed in rat (13) and mouse (14).
Since MEPE/OF45 was identiﬁed, its function related to
bone metabolism has been widely investigated. We show
here for the ﬁrst time that MEPE/OF45, as a co-factor of
CHK1, protects cells from DNA damage induced killing.
This work was initiated by looking for co-factor(s) of
CHK1 from one pair of transformed rat embryo
ﬁbroblasts: A1-5 and B4 cells.
Although A1-5 and B4 cells have similar genetic
backgrounds (15), as we reported previously, A1-5 cells
are much more resistant to IR or CPT induced killing
than B4 cells (5,6). The resistance of A1-5 cells to DNA
damage induced killing is due to the high levels of CHK1
(5,6). By looking for the co-factor(s) of CHK1 in A1-5
cells, we identiﬁed the new role of MEPE/OF45 in pro-
tecting cells from DNA damage induced killing. This new
role of MEPE/OF45 depends on the interaction of MEPE/
OF45 with CHK1, which maintains CHK1 levels by
reducing CHK1 degradation.
MATERIALS AND METHODS
PCR-select cDNA subtraction
RNA was extracted from A1-5 or B4 cells. By using the
PCR-select cDNA subtraction (PSDS) kit (Clontech
Laboratories, Inc.) (16), double-stranded cDNA was
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digested with RsaI and ligated with adapters according to
the manufacturer’s protocol. In the ﬁrst round, the cDNA
obtained from A1-5 cells was the tester and the cDNA
obtained from B4 cells was the driver. In the second
round, the cDNA obtained from A1-5 cells was the
driver and the cDNA obtained from B4 cells was the
tester. Two hybridizations were then performed. A sec-
ondary PCR ampliﬁcation was performed with nested
primers to further reduce any background PCR products
and enrich them for diﬀerentially expressed sequences. In
total 158 cDNA fragments were diﬀerentially expressed
between A1-5 and B4 cells by comparing the two
populations of mRNA. Eighty-one cDNA fragments
that were diﬀerent sections of the same gene were
excluded by analyzing the cDNA fragments in EST and
BLAST databases. The remaining 77 cDNA fragments
were individually labeled with a32P-dCTP by using a
random priming method and were hybridized with
the total RNAs from A1-5 or B4 cells. Ten of the 77
cDNA fragments were conﬁrmed and diﬀerentially
expressed between A1-5 and B4 cells by the hybridization.
The full length of one of the 10 cDNA fragments, which
showed less homology to any cDNA fragment in
EST and BLAST databases in early 2000, was cloned
by rapid ampliﬁcation of cDNA ends (RACE) with
the marathon DNA ampliﬁcation kit (Clontech Labora-
tories, Inc.).
RT–PCR
Total RNA was isolated from A1-5 and B4 cells by using
Trizol puriﬁcation kit (Invitrogen Corp.), according to the
manufacturer’s instructions. Two ml of RNA and 1 ml of
oligo dT primer were mixed with 10 ml of RNase free
water. The mixture was ﬁrst incubated at 70C for
10min, then was cooled down to room temperature.
Reverse transcription analyses were performed using the
RT–PCR kit (TaKaRa, Inc.), according to the manufac-
turer’s instructions. The primer sets used in this study
were: Mepe/Of45-forward, 50-CGG GAT CCC AGG
CTG TGT CTG-30; Mepe/Of45-reverse, 50-CGC AAG
CTT GCG AGA GCA GTG GTG ACT AG-30;
GAPDH-forward, 50-ACC ACA GTC CAT GCC ATC
ACT G-30; GAPDH-reverse, 50-GTC CAC CAC CCT
GTT GCT GTA G-30. The PCR (30 cycles) condition
was used as follows: denaturation at 95C for 5min,
then denaturation at 94C for 50 s, annealing at 55C for
50 s and elongation at 72C for 70 s, running 30 cycles. In
Mepe/Of45mRNA expression experiments, GAPDH was
used as a housekeeping gene.
Cell culture and antibodies
The transformed rat embryo ﬁbroblast cells, A1-5 and B4,
obtained from Dr A. Levine’s laboratory (15), were grown
in DMEM supplemented with 10% calf serum. The
antibody against rat MEPE/OF45 was made by our
laboratory. Brieﬂy, fragments of rat Mepe/Of45 cDNA
(100–498 bp) were generated by PCR with primers 50-CA
TATGAAGCTGAATGAAGAT-30 and 50-GGATCCTT
ACATTTGGGGGAGATG-30 and cloned in pET-
28a(+) plasmid (Novagen, Inc.). The protein was
expressed in BL21 (DE3) cells and puriﬁed by using
Ni-NTA spin columns (Qiagen, Inc.), according to the
manufacturer’s instructions. The puriﬁed protein was
analyzed by SDS-PAGE and was then injected into mice.
The antisera of MEPE/OF45 were collected and veriﬁed by
Western Blot. The antibody against C-terminal of human
MEPE/OF45 was as described (12,17). Puriﬁed HA-tagged
JNK2 protein (sc-4062) and antibodies against CHK1
(sc-8408 and sc-7898), HA (sc-805, sc-7392), PCNA
(sc-56), Cul4 (sc-10782), a-Tubulin (sc-8035), and
ubquitin (Ub) (sc-9133) were purchased from Santa Cruz
Biotechnology, Inc. The antibody against Cul1 was
purchased from Zymed Laboratories. The antibody
against GFP (AVAMM 26001) was purchased from
AVIVA System Biology, Inc. The antibody against H2A
(07–146) was purchased from Upstate Biotechnology, Inc.
The antibody against DsRed (632496) was purchased from
Clontech Laboratories, Inc.
Plasmid construction and transfections
The vector encoding antisense of rat Mepe/Of45 was
generated by using PCR with the primers 50-CG GGA
TCC ATG GTC ACC ACT GCT CTC-30 and 50-CGC
AAG CTT CTA CAG GCT GTG TCT GTT GG-30,
and was cloned into the plasmid pREP10 (Invitrogen
Corp.). The vector pLEGFP-C1 with NLS (Clontech
Laboratories, Inc.) encoding the full length cDNA of rat
Chk1 and/or the vector pDsRed1-N1 without NLS
(Clontech Laboratories, Inc.) encoding the full length
cDNA of rat Mepe/Of45 was generated. pREP10-HA
was generated by inserting the HA-tag into plasmid
pREP10. Wild-type MEPE/OF45 or MEPE/OF45
deleted mutants were cloned in pREP10-HA. GST-full-
length MEPE/OF45 or GST-truncated MEPE/OF45s
were generated by the standard methods. All the tags
including GST, red ﬂuorescence protein and HA were
designed at the C-terminal of MEPE/OF45. A1-5 or B4
cells were transfected with the empty plasmid, the plasmid
encoding the antisense of Mepe/Of45, wild-type Mepe/
Of45 or deletion mutant Mepe/Of45 by Lipofectamine
2000 (Invitrogen Corp.), according to the manufacturer’s
instructions. Stable cell lines were selected from
hygromycin resistant colonies and the transfected gene
was veriﬁed by PCR or by Western blot with an HA
antibody. In immunostaining experiments, the cells were
collected at 48 h after transfected or co-transfected with
the vector(s) (GFP-Chk1 in pLEGFP-C1 and red ﬂuores-
cence-Mepe/Of45 in pDsRed1-N1).
MEPE/OF45 siRNAs design and treatment
Rat Mepe/Of45 siRNAs (50-GGG ATC TAC TAC TCC
AGA AGA-30, 50-GAT AAT GAT GTC CCT CCT
TTC-30) were designed to speciﬁcally target the sequence
of 423–444 or 572–593 from the start codon region of the
rat Mepe/Of45. The siRNA of CHK1 is as previously
described (8). Human MEPE/OF45 siRNA (50-AAC
TAA GCA AAG CTG TGT GGA-30) was designed to
speciﬁcally target the sequence of 74–95 from the start
codon region of the human MEPE/OF45. These siRNAs
were synthesized by Dharmacon, Inc. Scrambled duplex
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RNAs (Dharmacon, Inc.) were used as the control
transfection. The RNAs were delivered to the cells by
OLIGOFECTAMINETM (Invitrogen Corp.), according
to the manufacturer’s instructions. The cells were
analyzed at 36–48 h post-transfection.
Yeast two hybrid assay
Rat Mepe/Of45 and rat Chk1 were expressed in both
pGBKT7 and pGADT7 (Clontech Laboratories, Inc.) as
fusion proteins. The interaction was monitored by the
ability of the transformants to grow on synthetic
medium lacking Leu, Trp and His according to the man-
ufacturer’s instructions, which occurred only when
MEPE/OF45 interacted with CHK1.
Fluorescence staining and immunoprecipitation (IP)
Cells transfected with vector pLEGFP-C1, containing
nuclei localization signal (NLS) encoding Chk1 and/or
vector pDsRed1-N1 encoding Mepe/Of45 were grown on
glass coverslips in 35mm dishes. Cells were ﬁxed with 4%
paraformaldehyde. The ﬂuorescent image was observed by
using a confocal laser microscope (Radiance 2100, Bio-
Rad Laboratories). IP was performed as described
previously (18). The samples were washed with the
buﬀer (0.5% NP-40, 1mM Na3VO4, 5mM NaF,
0.2mM PMSF in PBS buﬀer) and boiled in 30 ml of
protein loading buﬀer. The samples were loaded to 10%
Tris-PAGE gel followed by the standard Western Blot.
Cell sensitivity to DNA damage inducers
Surviving fractions were obtained from clonogenic assay
that was performed as previously described (5,6).
Premature chromatin condensation
In brief, 2 105 cells were plated, per 60mm dish with 3ml
of medium. Thirty hours later, cells were either treated
with 10 nM taxotere (to increase mitotic ratio) for 20 h,
and were irradiated with 10Gy or treated with 10 nM
taxotere and 2mM hydroxyurea (HU) for 20 h. Cells
were harvested with trypsin and a Premature chromatin
condensation (PCC) assay was performed as described
(19,20). Normal mitosis characteristics include well-
formed oblong chromatids present in pairs and at least
20 such chromosome pairs were found in a cluster.
Approximately 100 mitotic cells were counted per sample.
Ubiquitination assays
Cells were transiently transfected with a plasmid encoding
myc-ub [obtained from Dr. Chen’s and Dr. Yu’s labora-
tory (21)]. Thirty-six hours later the cells were in the
presence of 4 mM of LLnV for an additional 4 h. The
cells were collected and whole cell lyses were prepared.
Cell lyses (1mg) were mixed with 2 mg of CHK1
monoclonal antibody or Ub antibody and 20 ml of 50%
(v/v) protein A-Sepharose slurry (RepliGen) in 1ml of
buﬀer (0.5% NP40, 1mM Na3VO4, 5mM NaF and
0.2mM PMSF in PBS) and were rotated at 4C overnight.
The immune complexes were washed three times with the
same buﬀer, boiled with protein loading buﬀer and run on
SDS-PAGE gels. The gels were not cut or cut at the
site marked 60 kDa. The cut gel with >60 kDa samples
were immunoblotted with a-Ub antibody and the gel
with <60 kDa was immunoblotted with a-CHK1 poly-
clonal antibody. The non-cut gel was immunoblotted
with CHK1 antibody.
RESULTS AND DISCUSSION
MEPE/OF45 protects cells from DNA
damage-induced killing
To look for the co-factors of CHK1, we chose the PCR-
select cDNA subtraction (PSDS) approach to screen the
diﬀerent expressed genes between A1-5 cells and B4 cells.
By using this approach, we identiﬁed one fragment that
was expressed higher in A1-5 cells than in B4 cells
(Supplementary Figure S1A). RT–PCR results conﬁrmed
the diﬀerent expression between these two cell lines
(Supplementary Figure S1B) and the full length of this
gene cloned from our laboratory in late 2000
(Supplementary Figure S1C) was found to be identical
to the sequence of rat Mepe/Of45 published by another
group (13). The rat OF45 is the homologue of human
MEPE that was related to bone metabolism. However,
there was no report on the connection of MEPE/OF45
to DNA damage induced killing, and we were interested
in knowing whether the highly expressed MEPE/OF45
was related to the resistance of A1-5 cells. For this
purpose, we established stable cell lines that either
knocked down MEPE/OF45 in A1-5 cells or up-expressed
MEPE/OF45 in B4 cells and tested the sensitivities of
the cell lines to IR or CPT. The results showed that
when MEPE/OF45 was knocked down, the cells (Aa in
Figure 1A and A-a-MEPE/OF45 in Figure 1B) became
more sensitive to IR or CPT than the parental cell line
(A in Figure 1A and A1-5 in Figure 1B) and the cells
transfected with the vector alone (Ap in Figure 1A and
A-pREP10 in Figure 1B). The Mepe/Of45 siRNAs data
(Supplementary Figure S2) exclude the oﬀ-target eﬀects.
The cells became sensitive to DNA damage inducers when
either CHK1 alone was knocked down (5,6) or MEPE/
OF45 alone was knocked down (Figure 1B). To exclude
the possibility that the results reﬂected only in the partic-
ular cell lines, we examined the eﬀects of knocking down
MEPE/OF45 on human cell sensitivity to DNA damage
inducers. The results showed that similar to the REF cells,
knocking down MEPE/OF45 also sensitized HeLa cells to
DNA damage inducers (Supplementary Figure S3).
Interestingly, the cells could not increase their sensitivity
to DNA damage further when the two proteins were
knocked down at the same time (Supplementary Figure
S3), suggesting that MEPE/OF45 and CHK1 are in the
same pathway for protecting cells from DNA damage
induced killing. When the cells expressed with exogenous
wild-type MEPE/OF45 (Bw in Figure 1A and B-w-
MEPE/OF45 in Figure 1B), they became more resistant
to IR or CPT than the parental cell line (B in Figure 1A,
and B4 in Figure 1B) and the cells transfected with the
vector alone (Bp in Figure 1A and B-pREP10 in Figure
1B). These results demonstrate for the ﬁrst time that
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MEPE/OF45, the protein involved in bone metabolism,
does protect mammalian cells from DNA damage-
induced killing. These data indicate that MEPE/OF45 is
a multi-function protein. The relationship between the two
functions of MEPE/OF45 needs to be elucidated in the
future. Although CHK1 aﬀecting cell sensitivity to DNA
damage is involved in p53 stature (22), A1-5 and B4 cells
expressed similar levels of wild type and mutant p53 (15)
(our unpublished data), we could exclude the eﬀects of
p53 on the diﬀerent sensitivities of these cells to DNA
damage.
MEPE/OF45 interacts with CHK1
To test whether there was a functional link between
MEPE/OF45 and CHK1, we examined the physical inter-
action between MEPE/OF45 and CHK1 by using yeast
two-hybrid assay. The results showed that MEPE/OF45
did interact with CHK1 (Figure 2A). Although MEPE/
OF45 could be secreted to extracellular matrix (12,13),
the endogenous MEPE/OF45 in the cell is mainly
located in the nuclei, which is similar to CHK1 (Figure
2B, left panel). By using IP assay, we showed that the
endogenous MEPE/OF45 and CHK1 interacted with
each other (Figure 2B, right panel lanes 3 and 4), which
is not aﬀected by DNA damage (Supplementary Figure
S4). To conﬁrm the interaction of MEPE/OF45 with
CHK1 in vivo, we developed a simple method by using
two plasmids encoding either GFP-CHK1 fusion protein
with a nucleus localization signal (NLS) or red ﬂuores-
cence-MEPE/OF45 fusion protein without NLS.
Although the cDNA of Chk1 contains a NLS, partial
exogenous CHK1 would locate in cytoplasm without the
additional NLS in the plasmid (data not shown). The
results showed that the exogenous MEPE/OF45 alone
located mainly in the cytoplasm (Figure 2C, #1) and
the exogenous CHK1 alone located mainly in the
nuclei (Figure 2C, #2). However, when the cells were
co-transfected with these two genes, MEPE/OF45 was
Figure 1. MEPE/OF45 protects cells from DNA damage-induced
killing. (A) MEPE/OF45 and CHK1 levels were detected by Western
blot with whole cell lysates prepared from A1-5 cells (A), A1-5 cells
transfected with pREP10 vector alone (Ap), A1-5 cells transfected with
antisense MEPE/OF45 (Aa), B4 cells (B), B4 cells transfected with
pREP10 vector alone (Bp) and B4 cells transfected with wild-type
MEPE/OF45 (Bw). PCNA is used as an internal loading control. (B)
Cell lines (A1-5, A-pREP10, A-a-MEPE/OF45, B4, B-pREP10 and B-
w-MEPE/OF45) were either exposed to diﬀerent doses of X-rays or
treated with diﬀerent doses of CPT for 8 h. Surviving fractions were
obtained from clonogenic assay as previously described (5,6). The data
represented the average of three independent experiments and were
expressed as a percent of cell colonies without treatment.
Figure 2. MEPE/OF45 interacts with CHK1. (A) Yeast two-hybrid
results. Left panel. AH109 yeast cells transformed only with
recombinant plasmid DNAs were tested for self-activation on synthetic
medium SD/-Ade/-His/-Leu/-Trp. (1) positive control (pTD1-1 and
pVA3). (2) pGBKT7/Mepe/Of45 and pGADT7/Chk1. (3) pGBKT7/
Chk1 and pGADT7/Mepe/Of45. (4) pGBKT7/Mepe/Of45 and
pGADT7. (5) pGBKT7 and pGADT7/MEPE/OF45. Right panel.
Assays of b-galactosidase activity. (a) positive control (pTD1-1 and
pVA3). (b) pGBKT7/Mepe/Of45 and pGADT7/Chk1. (c) pGBKT7/
Chk1and pGADT7/Mepe/Of45. (d) pGBKT7/Mepe/Of45 and
pGADT7. Lanes 1–4 represent four repeat samples. (B) Cytoplasmic
(CE) or nucleic extracts (NE) were prepared from A1-5 cells. Left panel
represented the Western Blot signals detected directly from the extracts.
Right panel represented the signals detected from IP results. Lanes 1
and 2 showed the results from IP experiments that used general mouse
or rabbit serum as the negative controls. Lanes 3 and 4 indicated the
western blot signals of CHK1 or MEPE/OF45 from MEPE/OF45 or
CHK1 antibody immunoprecipitated complex. (C) Images of MEPE/
OF45 signal (red) and CHK1 signal (green) were detected in B4 cells
that were transfected with Mepe/Of45 alone (1), with Chk1 alone (2),
co-transfected with both Mepe/Of45 and Chk1 (3–5). Overlap of these
two images was shown in (5).
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merged with CHK1 to the nuclei (Figure 2C, #3–5),
indicating that the exogenous CHK1 interacted with the
exogenous MEPE/OF45 and pulled MEPE/OF45 into the
nucleus. These results provide additional evidence that
MEPE/OF45 interacts with CHK1.
MEPE/OF45 protecting cells from DNA damage-induced
killing depends on its interaction with CHK1
To identify the main domain of MEPE/OF45 interaction
with CHK1, we combined the approach described above
with GST-pull down assay to examine the interaction of
diﬀerent deleted MEPE/OF45 fragments with CHK1. We
discovered that the mutant MEPE/OF45 protein that
deleted 400–418 amino acids (aa) lost its major interaction
between MEPE/OF45 and CHK1 (the B4 cells transiently
co-transtected with pLEGFP-CHK1 and pDsRed-deleted
MEPE/OF45 #9, D9 in Supplementary Figure S5C
and D). Although the mutant MEPE/OF45 still showed
a weak interaction with CHK1 by IP assay (D9 in
Supplementary Figure S5D), it lost its ability to merge
with CHK1 when B4 cells were co-expressed with the
two proteins (Figure 3A). We then established stable cell
lines by expressing the wild-type MEPE/OF45 or the
mutant MEPE/OF45 in B4 cells. Interestingly, the HA-
tagged mutant MEPE/OF45 (deleted 400–418 aa) mainly
locates in the cytoplasm although the HA-tagged wild-
type MEPE/OF45 is still located in nuclei (Figure 3B,
Top-panel). The IP results further conﬁrm that the
400–418 aa of rat MEPE/OF45 is the main domain for
MEPE/OF45 interacting with CHK1 (Figure 3B,
Bottom-panel). More importantly, when B4 cells were
Figure 3. MEPE/OF45 protecting cells from DNA damage induced killing depends on its interaction with CHK1. (A) B4 cells were transiently
co-transfected with vector pLEGFP-C1 with NLS encoding CHK1 and vector pDsRed1-N1 without NLS encoding wild type or mutant MEPE/
OF45 (D9, See detail information in Supplementary Figure S5). The images are from one diversion (1D) or three diversions (3D) of observations.
(B) Top-panel: HA-MEPE/OF45 protein levels in cytoplasmic (CE) or nuclear extracts (NE) from established B4 cell lines that stable expressed
HA-wild-type MEPE/OF45 or HA-mutant MEPE/OF45. Puriﬁed HA-tagged JNK2 protein was used as HA positive control (lane 1). H2A or
a-Tubulin was used as an indicator for CE or NE. B4 cells without transfection were used as the negative control. Bw: B4 cells expressed with wild
type MEPE/OF45. Bm: B4 cells expressed with mutant MEPE/OF45. Bottom-panel: IP results. HA and CHK1 antibodies was used to detect MEPE/
OF45 interacting with CHK1. (C) Comparison of the sensitivities of B4, Bw and Bm cells to IR or CPT treatment (8 h). Data represented the average
of three independent experiments. (D) Cells were either treated with 10 nM taxotere for 20 h (to increase mitotic ratio), and irradiated with 10Gy or
treated with 10 nM taxotere and 2mM hydroxyurea (HU) for 20 h. The cells were then collected for PCC detection. Approximately 100 mitotic cells
(including normal and PCC) were counted per sample and PCC were expressed as a percentage of total mitosis. Data represent the average of three
independent experiments.
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transfected with the wild-type MEPE/OF45 (Bw in Figure
3B, B-w-MEPE/OF45 in Figure 3C) but not the mutant
MEPE/OF45 (Bm in Figure 3B, B-m-MEPE/OF45 in
Figure 3C), they became resistant to IR or CPT. These
results indicate that MEPE/OF45 protecting cells from
DNA damage-induced killing depends on its interaction
with CHK1. To further study the functional relationship
between MEPE/OF45 and CHK1, we examined the eﬀects
of MEPE/OF45 on premature chromatin condensation
(PCC) because CHK1 plays an essential role in preventing
DNA damage-induced PCC (19,20). The results showed
that the cells with higher expression of wild-type (A1-5,
A-p, B-w), but not mutant MEPE/OF45 (B-m) had less
DNA damage-induced PCC than the cells with lower
expression of MEPE/OF45 (A-a, B4 in Figure 3D). This
indicates that the interaction of MEPE/OF45 with CHK1
is important for MEPE/OF45 to protect cells from DNA
damage-induced PCC, further supporting that MEPE/
OF45 aﬀecting cellular response to DNA damage is
through the CHK1 pathway.
MEPE/OF45 protects CHK1 from ubiquitin-mediated
degradation
CHK1 is a fast turnover protein (23). MEPE/OF45 levels
correlate with the CHK1 levels in cells (Figure 1A and
Supplementary Figure S2). We were interested in
studying whether MEPE/OF45 played any role in
regulating CHK1 levels. We did not ﬁnd any apparent
diﬀerence in Chk1 mRNA levels between A1-5 and B4
cells (data not shown), excluding the possibility that
MEPE/OF45 aﬀects the transcription of Chk1, suggesting
that MEPE/OF45 protects CHK1 from degradation. To
test this hypothesis, we examined the half-life of CHK1 in
these cell lines. The results showed that CHK1 half-life
was longer in the cell lines with high levels of wild-type
MEPE/OF45 (A: A1-5; Ap: A1-5 transfected with empty
plasmid; Bw: B4 cells expressed with wild-type MEPE/
OF45 in Figure 4A) than that in the cell lines with low
levels of wild-type MEPE/OF45 (B: B4 cells; Aa: A1-5
cells with knocked down MEPE/OF45 in Figure 4A) or
with high levels of mutant MEPE/OF45 that lost interac-
tion with CHK1 (Bm: B4 cells expressed with the mutant
MEPE/OF45 in Figure 4). In order to clearly compare the
changes of CHK1 levels among diﬀerent cell lines, we
compared the initial levels of CHK1 at the 0 h point and
plotted the kinetics levels at diﬀerent times treated with
CHX (Supplementary Figure S6). These results show that
the interaction of MEPE/OF45 with CHK1 does play
an important role for stabilizing CHK1. Because CHK1
degradation occurs through the ubiquitin-proteasome
pathway (24), we wanted to know whether MEPE/OF45
aﬀected the ubiquitin-mediated proteolysis of CHK1. For
this purpose, we examined ubiquitinated CHK1 in these
cell lines. After transiently expressing Myc-ubiquitin in the
cell lines (Figure 4B), we examined the levels of CHK1
polyubiquitination in these Myc-ubiquitin expressed
cells. The results showed that the signals of CHK1
polyubiquitination were weaker in the cells with high
levels of wild-type MEPE/OF45 (A, Ap and Bw) than
that in the cells with low levels of MEPE/OF45 (B and
Figure 4. MEPE/OF45 reduces CHK1 from ubiquitin-mediated
degradation. (A) CHK1 half-life in diﬀerent cell lines: the cells were
treated with 100 mg/ml CHX at diﬀerent times. Whole cell lyses were
prepared. CHK1 signals were detected by Western blot. The CHK1
levels were plotted by using PhosphorImager with software
(ImageQuant) (Supplementary Figure S6). (B) Polyubiquitinated
CHK1 in diﬀerent cell lines. These cells were transfected with Myc-
ubiquitin. At 36 h after transfection, the cells were treated with 4mM
LLnV for additional 4 h and whole cell lyses were prepared. The top
panel showed the ubiquitin (Ub) signals from the cells before and after
Myc-Ub transfection. The bottom panel showed the Ub signals from
CHK1 IP complexes with the whole cell lyses (>60 kDa) and the CHK1
signals from the IP complexes (<60 kDa). (C) MEPE/OF45 aﬀects
CHK1 interacting with its E3 ligases, Cul1 or Cul4. The extracts
(CE: cytoplasmic extracts, NE: nucleic extracts) were mixed with
protein A conjugated with either Cul1 or Cul4 antibody for IP, and
CHK1 antibody was used for western blot analysis. (D) A model
explaining the possible mechanism by which MEPE/OF45 aﬀects
CHK1 degradation.
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Aa) or cells with high levels of mutant MEPE/OF45 (Bm)
(Figure 4B, Supplementary Figure S7). These results
provide direct evidence that supports that MEPE/OF45
plays an important role in delaying the ubiquitin-
mediated degradation of CHK1, and that the interaction
of MEPE/OF45 with CHK1 is an essential factor for such
functions.
The ubiquitination of CHK1 is mediated by E3 ligase
complexes containing Cul1 or Cul4A (24). To study
whether the interaction of MEPE/OF45 with CHK1
aﬀected the interaction of Cul1 or Cul4A with CHK1,
we examined the CHK1 levels in either Cul1 or Cul4A
immunoprecipitated complexes from extracts derived
from the cell lines. The results showed that the interaction
of CHK1 with either Cul1 or Cul4A was lower in the cells
with high levels of wild-type MEPE/OF45 than that in the
cells with low levels of MEPE/OF45 or with high levels of
mutant MEPE/OF45 (Figure 4C). These results indicate
that the level of CHK1 interaction with either Cul1 or
Cul4A is aﬀected by the interaction of MEPE/OF45
with CHK1 (Figure 4C). These results suggest a model
that the interaction of MEPE/OF45 with CHK1
competes with the interaction of either Cul1 or Cul4A
with CHK1, which in turn aﬀects CHK1 ubiquitin-
mediated degradation (Figure 4D). Conﬁrming this
hypothesis requires future identiﬁcation of the key
domain of CHK1 interacting with either MEPE/OF45
or the E3 ligases.
In summation, our results indicate that MEPE/OF45
protecting mammalian cells from DNA damage-induced
killing mainly depends on its interaction with CHK1. The
speciﬁc molecular mechanism can be linked to the
function of MEPE/OF45 to delay ubiquitin-mediated deg-
radation of CHK1 by competing with CHK1 E3 ligases.
Very interestingly, the role of MEPE/OF45 in protecting
rat cells from DNA damage induced killing through inter-
acting with CHK1 is similar to that shown in diﬀerent
human cell lines (Supplementary Figure S3 and our
unpublished data). These results indicate that MEPE/
OF45 is a new co-factor of CHK1, which could be a
new target for sensitizing cells for DNA damage
inducers and will beneﬁt cancer treatment.
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